TRENDS AND PROGNOSIS OF THE INCIDENCE OF AGE-RELATED MACULAR DEGENERATION IN THE ELDERLY WITH CHRONIC HEART FAILURE

2021 ◽  
pp. 140-145
Author(s):  
Виктор Афанасьевич Иванов ◽  
Борис Дмитриевич Жидких ◽  
Елена Ефимовна Атлас ◽  
Юрий Юрьевич Блинков ◽  
Татьяна Игоревна Субботина
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Macular Degeneration ◽  
Prognostic Model ◽  
The Elderly ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Medical Institutions ◽  
Time Period ◽  
Significant Difference

Возрастная макулярная дегенерация считается одной из распространенных возраст ассоциированных офтальмологических патологий, приводящих к полной или частичной потере зрения. Вероятность развития возрастной макулярной дегенерации существенно повышается при наличии сопутствующей хронической сердечной недостаточности. Однако изучение динамики заболеваемости возрастной макулярной дегенерацией при сочетании хронической сердечной недостаточности осуществляется крайне редко. Цель настоящего исследования - анализ заболеваемости возрастной макулярной дегенерацией и прогнозирование ее распространенности в Тамбовской области у пациентов с хронической сердечной недостаточностью. Исследование проводилось ретроспективным методом за 2013-2018 годы по данным официальной статистики лечебно-профилактических учреждений общего и специализированного профиля. При сборе информации использовались данные, содержащиеся в «Медицинской когорте амбулаторного больного», «Медицинской карте амбулаторного больного». Для прогнозирования заболеваемости возрастной макулярной дегенерацией использовался регрессионный анализ и программа «Statistica 10.0». В ходе исследования установлено повышение уровня заболеваемости с 13,54 случаев на 100 000 населения в 2013 году в базовом регионе до 28,42 случаев на 100 000 населения в 2018 году с достоверной разницей. Разработанная прогностическая модель у=0,7124 ln(x1)+1,4586 показывает, что в 2019-2021 годах произойдет дальнейшее увеличение заболеваемости возрастной макулярной дегенерацией. При этом наибольшую распространенность среди выделяемых форм возрастной макулярной дегенерации в Тамбовской области за исследуемый временной период имеет неэкссудативная форма, варьирующая в диапазоне от 12,41 случаев до 25,98 случаев на 100 000 населения (р<0,001). Экссудативная возрастная макулярная дегенерация варьирует от 1,42 случаев до 2,30 случаев на 100 000 жителей области. Полученные данные представляют интерес для принятия упреждающих профилактических мероприятий по стабилизации заболеваемости возрастной макулярной дегенерацией Age-related macular degeneration is considered one of the most common age-associated ophthalmological pathologies leading to complete or partial loss of vision. The probability of developing age-related macular degeneration increases significantly in the presence of concomitant chronic heart failure. However, the study of the dynamics of the incidence of age-related macular degeneration in combination with chronic heart failure is extremely rare. The purpose of this study is to analyze the incidence of age-related macular degeneration and predict its prevalence in the Tambov region in patients with chronic heart failure. The study was conducted retrospectively for 2013-2018 according to official statistics of general and specialized medical institutions. When collecting information, the data contained in the "Medical cohort of an outpatient patient", "The medical record of an outpatient patient" were used. Regression analysis and the Statistica 10.0 program were used to predict the incidence of age-related macular degeneration. The study found an increase in the incidence rate from 13.54 cases per 100,000 population in 2013 in the base region to 28.42 cases per 100,000 population in 2018 with a significant difference. The developed prognostic model y1=0.7124 ln(x1)+1.4586 shows that in 2019-2021 there will be a further increase in the incidence of age-related macular degeneration. At the same time, the greatest prevalence among the isolated forms of age-related macular degeneration in the Tambov region over the studied time period has a non-exudative form, varying in the range from 12.41 cases to 25.98 cases per 100,000 population (p<0.001). Exudative age-related macular degeneration varies from 1.42 cases to 2.30 cases per 100,000 inhabitants of the region. The data obtained are of interest for taking proactive preventive measures to stabilize the incidence of age-related macular degeneration

scholarly journals Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Shigeru Honda ◽  
Yasuo Yanagi ◽  
Hideki Koizumi ◽  
Yirong Chen ◽  
Satoru Tanaka ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Productivity Loss ◽  
Work Productivity ◽  
The Elderly ◽  
Developed Countries ◽  
Age Related Macular Degeneration ◽  
Resource Utilisation ◽  
Total Work ◽  
Healthcare Resource Utilisation ◽  
Age Related

AbstractThe chronic eye disorder, neovascular age-related macular degeneration (nAMD), is a common cause of permanent vision impairment and blindness among the elderly in developed countries, including Japan. This study aimed to investigate the disease burden of nAMD patients under treatment, using data from the Japan National Health and Wellness surveys 2009–2014. Out of 147,272 respondents, 100 nAMD patients reported currently receiving treatment. Controls without nAMD were selected by 1:4 propensity score matching. Healthcare Resource Utilisation (HRU), Health-Related Quality of Life (HRQoL), and work productivity loss were compared between the groups. Regarding HRU, nAMD patients had significantly increased number of visits to any healthcare provider (HCP) (13.8 vs. 8.2), ophthalmologist (5.6 vs. 0.8), and other HCP (9.5 vs. 7.1) compared to controls after adjusting for confounding factors. Additionally, nAMD patients had reduced HRQoL and work productivity, i.e., reduced physical component summary (PCS) score (46.3 vs. 47.9), increased absenteeism (18.14% vs. 0.24%), presenteeism (23.89% vs. 12.44%), and total work productivity impairment (33.57% vs. 16.24%). The increased number of ophthalmologist visits were associated with decreased PCS score, increased presenteeism and total work productivity impairment. The current study highlighted substantial burden for nAMD patients, requiring further attention for future healthcare planning and treatment development.

scholarly journals Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy

2021 ◽  
Vol 22 (3) ◽  
pp. 1170
Author(s):  
Arunbalaji Pugazhendhi ◽  
Margaret Hubbell ◽  
Pooja Jairam ◽  
Balamurali Ambati
Keyword(s):  
Risk Factors ◽  
Macular Degeneration ◽  
Kinase Inhibitors ◽  
Rho Kinase ◽  
The Elderly ◽  
Age Related Macular Degeneration ◽  
Gene Therapies ◽  
Rho Kinase Inhibitors ◽  
Age Related ◽  
Endothelial Growth Factor

Neovascular age-related macular degeneration (exudative or wet AMD) is a prevalent, progressive retinal degenerative macular disease that is characterized by neovascularization of the choroid, mainly affecting the elderly population causing gradual vision impairment. Risk factors such as age, race, genetics, iris color, smoking, drinking, BMI, and diet all play a part in nvAMD’s progression, with anti-vascular endothelial growth factor (anti-VEGF) therapy being the mainstay of treatment. Current therapeutic advancements slow the progression of the disease but do not cure or reverse its course. Newer therapies such as gene therapies, Rho-kinase inhibitors, and levodopa offer potential new targets for treatment.

scholarly journals Effect of Ranibizumab Treatment in Cases of Choroidal Neovascular Membranes Secondary to Pathological Myopia versus Age-Related Macular Degeneration

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
M S Abdaltawab ◽  
Z F Ismail ◽  
W M A Ebeid ◽  
S M Fawzy
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Intravitreal Injections ◽  
P Value ◽  
Newly Diagnosed ◽  
Pathological Myopia ◽  
Age Related ◽  
Significant Difference ◽  
The Mean

Abstract Aim of the Work The aim of this work is to compare the response of treatment with ranibizumab in terms of visual acuity in cases of CNV secondary to pathological myopia versus CNV secondary to age-related macular degeneration. Methods This prospective, comparative study included ten eyes newly diagnosed as having CNV secondary to pathological myopia, and 10 eyes newly diagnosed as having subfoveal active CNV secondary to AMD. All patients had 3 monthly intravitreal Injections of 0.50 mg (in 0.05 ml of solution) ranibizumab with monthly evaluation of best corrected visual acuity (BCVA) by Landolt C chart, and also calculated in Logarithm of Minimum Angle of Resolution (Log MAR). Results pretreatment there was no significant difference between the two groups as the mean VA (Log Mar) was 1.31 ± 0.2 in AMD group and 1.17 ± 0.3 in MCNV group of P value = 0.431 and also post three IVI of ranibizumab showed no significant difference between the two groups as the mean VA (Log Mar) was 1.22 ± 0.2 for AMD and 1.22 ± 0.5 for MCNV of P value = 0.635. Conclusion there was no significant difference in BCVA between AMD and MCNV groups after three intravitreal injections of ranibizumab.

scholarly journals Introduction to the multi-author review on macular degeneration

2020 ◽  
Vol 77 (5) ◽  
pp. 779-780 ◽  
Author(s):  
Anu Kauppinen
Keyword(s):  
Macular Degeneration ◽  
Vision Loss ◽  
The Elderly ◽  
Developed Countries ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Severe Vision Loss ◽  
Author Review ◽  
Dry Amd ◽  
Endothelial Growth Factor

AbstractProlonged life expectancies contribute to the increasing prevalence of age-related macular degeneration (AMD) that is already the leading cause of severe vision loss among the elderly in developed countries. In dry AMD, the disease culminates into vast retinal atrophy, whereas the wet form is characterized by retinal edema and sudden vision loss due to neovascularization originating from the choroid beneath the Bruch’s membrane. There is no treatment for dry AMD and despite intravitreal injections of anti-vascular endothelial growth factor (VEGF) that suppress the neovessel formation, also wet AMD needs new therapies to prevent the disease progression and to serve patients lacking of positive response to current medicines. Knowledge on disease mechanisms is a prerequisite for the drug development, which is hindered by the multifactorial nature of AMD. Numerous distinguished publications have revealed AMD mechanisms at the cellular and molecular level and in this multi-author review, we take a bit broader look at the topic with some novel aspects.

scholarly journals Development of an ultra-sensitive human IL-33 biomarker assay for age-related macular degeneration and asthma drug development

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Elaine Mai ◽  
Joyce Chan ◽  
Levina Goon ◽  
Braeden K. Ego ◽  
Jack Bevers ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Inflammatory Diseases ◽  
Interleukin 1 ◽  
Age Related Macular Degeneration ◽  
Reduced Form ◽  
Enzyme Linked Immunosorbent Assay ◽  
Interleukin 33 ◽  
Age Related ◽  
Significant Difference ◽  
High Concentrations

Abstract Background Over the past decade, human Interleukin 33 (hIL-33) has emerged as a key contributor to the pathogenesis of numerous inflammatory diseases. Despite the existence of several commercial hIL-33 assays spanning multiple platform technologies, their ability to provide accurate hIL-33 concentration measurements and to differentiate between active (reduced) and inactive (oxidized) hIL-33 in various matrices remains uncertain. This is especially true for lower sample volumes, matrices with low hIL-33 concentrations, and matrices with elevated levels of soluble Interleukin 1 Receptor-Like 1 (sST2), an inactive form of ST2 that competes with membrane bound ST2 for hIL-33 binding. Results We tested the performance of several commercially available hIL-33 detection assays in various human matrices and found that most of these assays lacked the sensitivity to accurately detect reduced hIL-33 at biologically relevant levels (sub-to-low pg/mL), especially in the presence of human sST2 (hsST2), and/or lacked sufficient target specificity. To address this, we developed and validated a sensitive and specific enzyme-linked immunosorbent assay (ELISA) capable of detecting reduced and total hIL-33 levels even in the presence of high concentrations of sST2. By incorporating the immuno-polymerase chain reaction (iPCR) platform, we further increased the sensitivity of this assay for the reduced form of hIL-33 by ~ 52-fold. Using this hIL-33 iPCR assay, we detected hIL-33 in postmortem human vitreous humor (VH) samples from donors with age-related macular degeneration (AMD) and found significantly increased hIL-33 levels when compared to control individuals. No statistically significant difference was observed in aqueous humor (AH) from AMD donors nor in plasma and nasosorption fluid (NF) from asthma patients compared to control individuals. Conclusions Unlike existing commercial hIL-33 assays, our hIL-33 bioassays are highly sensitive and specific and can accurately quantify hIL-33 in various human clinical matrices, including those with high levels of hsST2. Our results provide a proof of concept of the utility of these assays in clinical trials targeting the hIL-33/hST2 pathway.

AN AUTOMATED METHOD TO DETECT AGE-RELATED MACULAR DEGENERATION FROM OPTICAL COHERENCE TOMOGRAPHIC IMAGES

2021 ◽  
pp. 2150036
Author(s):  
Anju Thomas ◽  
P. M. Harikrishnan ◽  
Varun P. Gopi ◽  
P. Palanisamy
Keyword(s):  
Early Detection ◽  
Macular Degeneration ◽  
The Elderly ◽  
Age Related Macular Degeneration ◽  
Data Sets ◽  
Sigmoid Function ◽  
Data Set ◽  
Automated Method ◽  
Age Related ◽  
Sd Oct

Age-related macular degeneration (AMD) is an eye disease that affects the elderly. AMD’s prevalence is increasing as society’s population ages; thus, early detection is critical to prevent vision loss in the elderly. Arrangement of a comprehensive examination of the eye for AMD detection is a challenging task. This paper suggests a new poly scale and dual path (PSDP) convolutional neural network (CNN) architecture for early-stage AMD diagnosis automatically. The proposed PSDP architecture has nine convolutional layers to classify the input image as AMD or normal. A PSDP architecture is used to enhance classification efficiency due to the high variation in size and shape of perforation present in OCT images. The poly scale approach employs filters of various sizes to extract features from local regions more effectively. Simultaneously, the dual path architecture incorporates features extracted from different CNN layers to boost features in the global regions. The sigmoid function is used to classify images into binary categories. The Mendeley data set is used to train the proposed network and tested on Mendeley, Duke, SD-OCT Noor, and OCTID data sets. The testing accuracy of the network in Mendeley, Duke, SD-OCT Noor, and OCT-ID is 99.73%,96.66%,94.89%,99.61%, respectively. The comparison with alternative approaches showed that the proposed algorithm is efficient in detecting AMD. Despite having been trained on the Mendeley data set, the proposed model exhibited good detection accuracy when tested on other data sets. This shows that the suggested model can distinguish AMD/Normal images from various data sets. As compared to other methods, the findings show that the proposed algorithm is efficient at detecting AMD. Rapid eye scanning for early detection of AMD could be possible with the proposed architecture. The proposed CNN can be applied in real-time due to its lower complexity and less learnable parameters.

Epidemiology Prevalence and Incidence in Dry-Form (Non-Neovascular) Age-Related Macular Degeneration

2017 ◽  
pp. 97-99
Keyword(s):  
Macular Degeneration ◽  
Elderly Population ◽  
The Elderly ◽  
Epidemiologic Studies ◽  
Age Related Macular Degeneration ◽  
Neovascular Amd ◽  
Age Related ◽  
Dry Amd ◽  
Degenerative Disorder ◽  
Definition Of

Age-related macular degeneration (AMD) is a degenerative disorder of the central retina and represents the leading cause of severe visual impairment in the elderly population of industrialized societies. It is known that it currently exists between 30 and 50 million people around the world and is estimated that will have doubled by the end of the coming decade. Several large epidemiologic studies have evaluated the prevalence of non-neovascular or so-called dry AMD. There is some variation in the prevalence of non-neovascular AMD depending on the exact definition of AMD. All of them report a higher prevalence of early AMD and an increasing prevalence with age. It is seen most in Caucasians and least in people with Africans and it is not related to gender.

scholarly journals Efficacy Comparison of Intravitreal Anti-VEGF Therapy for Three Subtypes of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Jianqing Li ◽  
Jiayi Xu ◽  
Yiyi Chen ◽  
Jiaju Zhang ◽  
Yihong Cao ◽  
...  
Keyword(s):  
Systematic Review ◽  
Macular Degeneration ◽  
Meta Analysis ◽  
Age Related Macular Degeneration ◽  
Cochrane Library ◽  
Anti Vegf ◽  
Age Related ◽  
Significant Difference ◽  
The Mean

Purpose. Intravitreal antivascular endothelial growth factor (anti-VEGF) therapy has been widely used for the treatment of neovascularization (NV) secondary to age-related macular degeneration (AMD). This study aimed to compare the efficacy among different subtypes of neovascular age-related macular degeneration (nAMD). Methods. PubMed, Embase, and the Cochrane Library were searched for eligible studies. We performed meta-analysis using Review Manager 5.3 and Stata/SE 12.0. Results. A total of 24 studies met our inclusion criteria and were included in the systematic review. At 3 months, the mean logarithm of the minimum angle of resolution (logMAR) improvements were −0.09, −0.18, and −0.23 for type 1, 2, and 3, respectively, while the mean macular thickness (MT) changes were −104.83, −130.76, and −196.29 μm. At 12 months, the mean changes in Early Treatment of Diabetic Retinopathy Study (ETDRS) letters were 6.38, 8.12, and 9.37, while the MT decrease was 126.51, 126.52, and 139.85 μm, respectively. However, statistically significant difference was only found between type 1 and 3 in vision improvement, both in the short term (p=0.0002) and long term (p=0.01). Conclusions. The reactivity to VEGF inhibitors varied among different subtypes of nAMD. The efficacy of intravitreal anti-VEGF therapy in type 3 nAMD was statistically better than type 1 when considering vision improvement at 3 and 12 months. Thus, the lesion subtype is a predictor for the treatment outcome which can help guide prognosis.

Sign in / Sign up

Export Citation Format

Share Document